vs
金罗斯黄金（GOLD）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是金罗斯黄金的1.5倍（$219.9M vs $148.1M），金罗斯黄金净利率更高（7.9% vs -1.0%，领先8.9%），Orthofix Medical Inc.同比增速更快（2.0% vs -94.6%），Orthofix Medical Inc.自由现金流更多（$16.8M vs $-46.6M），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs -76.2%）
金罗斯黄金公司是一家总部位于加拿大多伦多的金银开采企业，成立于1993年。目前公司共运营六座在产金矿，矿区分布在巴西、毛里塔尼亚与美国境内，在2019年InvestingNews评选的全球十大黄金开采企业中位列第五。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
GOLD vs OFIX — 直观对比
营收规模更大
OFIX
是对方的1.5倍
$148.1M
营收增速更快
OFIX
高出96.6%
-94.6%
净利率更高
GOLD
高出8.9%
-1.0%
自由现金流更多
OFIX
多$63.4M
$-46.6M
两年增速更快
OFIX
近两年复合增速
-76.2%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $148.1M | $219.9M |
| 净利润 | $11.6M | $-2.2M |
| 毛利率 | 63.0% | 71.1% |
| 营业利润率 | 10.7% | 0.2% |
| 净利率 | 7.9% | -1.0% |
| 营收同比 | -94.6% | 2.0% |
| 净利润同比 | 77.4% | 92.4% |
| 每股收益（稀释后） | $0.46 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GOLDOFIX
| Q4 25 | $148.1M | $219.9M | ||
| Q3 25 | $3.7B | $205.6M | ||
| Q2 25 | $2.5B | $203.1M | ||
| Q1 25 | $3.0B | $193.6M | ||
| Q4 24 | $2.7B | $215.7M | ||
| Q3 24 | $2.7B | $196.6M | ||
| Q2 24 | $2.5B | $198.6M | ||
| Q1 24 | $2.6B | $188.6M |
净利润GOLDOFIX
| Q4 25 | $11.6M | $-2.2M | ||
| Q3 25 | $-939.0K | $-22.8M | ||
| Q2 25 | $10.3M | $-14.1M | ||
| Q1 25 | $-8.5M | $-53.1M | ||
| Q4 24 | $6.6M | $-29.1M | ||
| Q3 24 | $9.0M | $-27.4M | ||
| Q2 24 | $30.9M | $-33.4M | ||
| Q1 24 | $5.0M | $-36.0M |
毛利率GOLDOFIX
| Q4 25 | 63.0% | 71.1% | ||
| Q3 25 | 2.0% | 72.2% | ||
| Q2 25 | 3.3% | 68.7% | ||
| Q1 25 | 1.4% | 62.8% | ||
| Q4 24 | 1.6% | 69.0% | ||
| Q3 24 | 1.6% | 68.7% | ||
| Q2 24 | 1.7% | 67.8% | ||
| Q1 24 | 1.3% | 67.5% |
营业利润率GOLDOFIX
| Q4 25 | 10.7% | 0.2% | ||
| Q3 25 | -0.0% | -8.3% | ||
| Q2 25 | 0.5% | -7.9% | ||
| Q1 25 | -0.3% | -25.2% | ||
| Q4 24 | 0.3% | -5.3% | ||
| Q3 24 | 0.4% | -9.6% | ||
| Q2 24 | 1.3% | -12.5% | ||
| Q1 24 | 0.2% | -15.6% |
净利率GOLDOFIX
| Q4 25 | 7.9% | -1.0% | ||
| Q3 25 | -0.0% | -11.1% | ||
| Q2 25 | 0.4% | -6.9% | ||
| Q1 25 | -0.3% | -27.4% | ||
| Q4 24 | 0.2% | -13.5% | ||
| Q3 24 | 0.3% | -13.9% | ||
| Q2 24 | 1.2% | -16.8% | ||
| Q1 24 | 0.2% | -19.1% |
每股收益（稀释后）GOLDOFIX
| Q4 25 | $0.46 | $-0.05 | ||
| Q3 25 | $-0.04 | $-0.57 | ||
| Q2 25 | $0.43 | $-0.36 | ||
| Q1 25 | $-0.36 | $-1.35 | ||
| Q4 24 | $0.27 | $-0.76 | ||
| Q3 24 | $0.37 | $-0.71 | ||
| Q2 24 | $1.29 | $-0.88 | ||
| Q1 24 | $0.21 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $82.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $653.8M | $450.0M |
| 总资产 | $3.8B | $850.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资GOLDOFIX
| Q4 25 | — | $82.0M | ||
| Q3 25 | — | $62.9M | ||
| Q2 25 | — | $65.6M | ||
| Q1 25 | — | $58.0M | ||
| Q4 24 | — | $83.2M | ||
| Q3 24 | — | $30.1M | ||
| Q2 24 | — | $26.4M | ||
| Q1 24 | — | $27.0M |
总债务GOLDOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | $157.2M | ||
| Q2 25 | — | $157.0M | ||
| Q1 25 | — | $156.9M | ||
| Q4 24 | — | $157.0M | ||
| Q3 24 | — | $118.5M | ||
| Q2 24 | — | $118.0M | ||
| Q1 24 | — | $118.2M |
股东权益GOLDOFIX
| Q4 25 | $653.8M | $450.0M | ||
| Q3 25 | $644.0M | $442.5M | ||
| Q2 25 | $649.5M | $458.3M | ||
| Q1 25 | $643.6M | $458.3M | ||
| Q4 24 | $612.7M | $503.1M | ||
| Q3 24 | $611.1M | $525.9M | ||
| Q2 24 | $607.6M | $546.0M | ||
| Q1 24 | $583.2M | $570.3M |
总资产GOLDOFIX
| Q4 25 | $3.8B | $850.6M | ||
| Q3 25 | $2.6B | $832.6M | ||
| Q2 25 | $2.2B | $837.2M | ||
| Q1 25 | $2.2B | $823.1M | ||
| Q4 24 | $1.9B | $893.3M | ||
| Q3 24 | $2.0B | $867.9M | ||
| Q2 24 | $1.8B | $882.0M | ||
| Q1 24 | $1.7B | $906.0M |
负债/权益比GOLDOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | — | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× | ||
| Q1 24 | — | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-42.6M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $-46.6M | $16.8M |
| 自由现金流率自由现金流/营收 | -31.5% | 7.6% |
| 资本支出强度资本支出/营收 | 2.7% | 4.9% |
| 现金转化率经营现金流/净利润 | -3.66× | — |
| 过去12个月自由现金流最近4个季度 | $310.3M | $-1.3M |
8季度趋势，按日历期对齐
经营现金流GOLDOFIX
| Q4 25 | $-42.6M | $27.7M | ||
| Q3 25 | $195.4M | $12.4M | ||
| Q2 25 | $67.0M | $11.6M | ||
| Q1 25 | $102.8M | $-18.4M | ||
| Q4 24 | $110.1M | $23.7M | ||
| Q3 24 | $-127.5M | $11.7M | ||
| Q2 24 | $82.8M | $9.0M | ||
| Q1 24 | $79.8M | $-18.6M |
自由现金流GOLDOFIX
| Q4 25 | $-46.6M | $16.8M | ||
| Q3 25 | $193.4M | $2.5M | ||
| Q2 25 | $63.1M | $4.5M | ||
| Q1 25 | $100.4M | $-25.1M | ||
| Q4 24 | $106.4M | $15.2M | ||
| Q3 24 | $-128.1M | $6.3M | ||
| Q2 24 | $80.1M | $-360.0K | ||
| Q1 24 | $79.1M | $-29.1M |
自由现金流率GOLDOFIX
| Q4 25 | -31.5% | 7.6% | ||
| Q3 25 | 5.3% | 1.2% | ||
| Q2 25 | 2.5% | 2.2% | ||
| Q1 25 | 3.3% | -13.0% | ||
| Q4 24 | 3.9% | 7.0% | ||
| Q3 24 | -4.7% | 3.2% | ||
| Q2 24 | 3.2% | -0.2% | ||
| Q1 24 | 3.0% | -15.4% |
资本支出强度GOLDOFIX
| Q4 25 | 2.7% | 4.9% | ||
| Q3 25 | 0.1% | 4.8% | ||
| Q2 25 | 0.2% | 3.5% | ||
| Q1 25 | 0.1% | 3.5% | ||
| Q4 24 | 0.1% | 4.0% | ||
| Q3 24 | 0.0% | 2.7% | ||
| Q2 24 | 0.1% | 4.7% | ||
| Q1 24 | 0.0% | 5.6% |
现金转化率GOLDOFIX
| Q4 25 | -3.66× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 6.49× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 16.78× | — | ||
| Q3 24 | -14.20× | — | ||
| Q2 24 | 2.68× | — | ||
| Q1 24 | 15.91× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GOLD
暂无分部数据
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
